Plasma Clinical Trials

141 recruitingLast updated: June 20, 2026

There are 141 actively recruiting plasma clinical trials across 52 countries. Studies span Phase 2, Phase 1, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Seattle, Washington, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Plasma Trials at a Glance

141 actively recruiting trials for plasma are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Phase 2 with 45 trials, with the heaviest enrollment activity in Houston, Seattle, and New York. Lead sponsors running plasma studies include M.D. Anderson Cancer Center, Institute of Hematology & Blood Diseases Hospital, China, and Fred Hutchinson Cancer Center.

Treatments under study

About Plasma Clinical Trials

Looking for clinical trials for Plasma? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Plasma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Plasma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 141 trials

Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled580 locationsNCT03866382
Recruiting
Phase 2

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled9 locationsNCT07231952
Recruiting
Phase 3

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

RISS Stage I Plasma Cell MyelomaRISS Stage II Plasma Cell MyelomaPlasma Cell Myeloma
ECOG-ACRIN Cancer Research Group1,450 enrolled649 locationsNCT04566328
Recruiting
Phase 3

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma
ECOG-ACRIN Cancer Research Group288 enrolled747 locationsNCT03937635
Recruiting
Early Phase 1

64Cu-LLP2A for Imaging Hematologic Malignancies

Chronic Lymphocytic LeukemiaMultiple MyelomaFollicular Lymphoma+4 more
Washington University School of Medicine42 enrolled1 locationNCT06636175
Recruiting
Phase 1

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute72 enrolled3 locationsNCT03113643
Recruiting
Not Applicable

Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)

Breast CancerPlatelet-Rich PlasmaLipofilling+1 more
The Leningrad Regional Clinical Hospital30 enrolled1 locationNCT07658170
Recruiting
Phase 2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled133 locationsNCT04840602
Recruiting
Phase 1Phase 2

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory
Sanofi258 enrolled26 locationsNCT04643002
Recruiting

Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis

Knee OsteoarthritisHyaluronic AcidPlatelet-Rich Plasma
Centre Hospitalier Universitaire, Amiens100 enrolled1 locationNCT05039463
Recruiting
Phase 1

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Multiple MyelomaPlasma Cell Myeloma
Robert Flavell, MD, PhD20 enrolled1 locationNCT05892393
Recruiting
Phase 3

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma
SWOG Cancer Research Network510 enrolled397 locationsNCT05561387
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Early Phase 1

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command20 enrolled1 locationNCT07519187
Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Immune Oncology Research Institute200 enrolled22 locationsNCT05430971
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 2

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Multiple MyelomaPlasma Cell Leukemia
University of Utah120 enrolled1 locationNCT05405387
Recruiting
Not Applicable

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Bone PainMetastatic Malignant Neoplasm in the BonePlasma Cell Myeloma
University of Southern California100 enrolled9 locationsNCT03858205
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545